Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: Initial experience

Transfusion

Volumn 46, Issue 4, 2006, Pages 624-629

  Schinzel, Helmut ^a   Berghoff, Karin ^b   Beuermann, Ingrid ^b   Sauer, Oliver ^b   Von MacH, Marc Alexander ^b   Weilemann, Ludwig Sacha ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TRANSACTIVATOR PROTEIN;

ANTICOAGULATION; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL MONITORING; BLOOD SAMPLING; BODY WEIGHT; CAPILLARY WALL; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; GUILLAIN BARRE SYNDROME; HUMAN; MEASUREMENT; MEMBRANE FILTER; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; PLASMA TRANSFUSION; PLASMA VOLUME; PLASMAPHERESIS; SINGLE DRUG DOSE;

ADULT; ANTICOAGULANTS; DALTEPARIN; GUILLAIN-BARRE SYNDROME; HUMANS; MONITORING, PHYSIOLOGIC; MYASTHENIA GRAVIS; PLASMAPHERESIS;

EID: 33645325148     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00755.x     Document Type: Article

References (29)

1. Madore F. Plasmapheresis: technical aspects and indications. Crit Care Clin 2002 18 375 92.
2. Baeyer H. Plasmapheresis in immune haematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience. Ther Apher Dial 2003 7 127 40.
3. Guillevin L Pagnoux C. Indications of plasma exchange for systemic vasculitis. Ther Apher Dial 2003 7 155 60.
4. Nogates-Gaete J Valenzuela D Liendo F et al. Plasmapheresis in neurological diseases: experience in 140 procedures in 47 patients. Rev Med Chil 2004 123 295 8.
5. Heimark RL Kurachi RK Fujikawa K Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980 286 456 560.
6. Morales M Pizzuto J Reyna MA et al. Use of heparin for cytapheresis and plasmapheresis in a continuous flow centrifuge. Transfusion 1982 22 384 7.
7. Frasca GM Buscaroli A Borgnino LC Vangelista A. Optimzation of heparin anticoagulation during membrane plasma separation. J Artif Organs 1988 11 313 6.
8. Hosokawa S Oyamaguchi A Yoshida O. Optimization of heparinization in clinical double filtration plasmapheresis. Int J Artif Organs 1989 12 544 8.
9. Hosokawa S Oyamaguchi A Yoshida O. Clinical studies on adequate dosage of heparin during immunoadorption with membrane plasmapheresis. J Clin Apheresis 1990 5 197 200.
10. Omokawa S Malchesky PS Yamashita M et al. Effect of anticoagulant on biocompatibility in membrane plasmapheresis. Int J Artif Organs 1990 13 768 77.
11. Unger KU Haltern C Dohmen B Rossaint R. Influence of different heparin concentrations on the results of in vitro investigations in plasmaseperation technology using capillary membrane filters. Artif Organs 2003 27 649 57.
12. Sabloff M Wells PS. The effect of plasmapheresis on the serum activity level of dalteparin: a case report. Blood Coagul Fibrinolysis 2000 11 395 400.
13. Pelzer H Schwarz A Heimburger N. Determination of human thrombin- antithrombin III-complex in plasma with an enzym-linked immunosorbent assay. Thromb Haemost 1988 59 101 6.
14. Pelzer H Schwarz A Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991 65 153 9.
15. Teiel JM Bauer KA Lau HK Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2-fragment and thrombin-antithrombin-complex. Blood 1982 59 1086 97.
16. Bruhn HD Conard J Manucci M et al. Multicentric evaluation of a new assay for prothrombin fragment 1+2 determination. Thromb Haemost 1992 68 413 7.
17. Holmer E et al. A simple chromogenic assay for heparin and heparin-linked anti-F Xa acitivity in plasma. Thromb Haemost 1985 53 278 81.
18. Barrowcliffe TW. An international standard for low molecular weight heparin. Thromb Haemost 1988 60 1 7.
19. Anastassiades EG Lane DA Lynn A Curtis JR. Preliminary evaluation of repeated use of a low molecular weight heparin in hemodialysis for chronic renal failure. Proc Eur Dial Trans Assoc 1985 22 329 33.
20. Lane DA Ireland H Flynn A Anastassiades E Curtis JR. Hemodialysis with low molecular weight heparin: dosage requirement for the elimination of extracorporeal fibrin formation. Nephrol Dial Transplant 1986 1 179 35.
21. Ljunberg B Blombäck M Johnsson H Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987 27 31 5.
22. Swars H Hafner G Weilemann LS et al. Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®). Intens Care Med 1991 17 52 6.
23. Suzuki T Ota K Naganuma S et al. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan. Semin Thromb Hemost 1990 16 46 54.
24. Sagedal S Hartmann A Sundstrom K et al. A single dose of dalteparin effectively prevent clotting during haemodialysis: anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 1999 14 1943 7.
25. Sagedal S Hartmann A Sundstrom K Bjornsen S Brosstad F. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001 16 987 93.
26. Warkentin TE Chong BH Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998 79 1 7.
27. Laptosa M Green K Elizabeth MV et al. College of American Pathologists Conference XXXI on Laboratory Monitorin of Anticoagulant Therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998 122 799 807.
28. Harenberg J. Is laboratory monitoring of low-molecular-weight heaprin therapy necessary? Yes. J Thromb Haemost 2004 2 547 50.
29. Nieuwenhuis HK Albada J Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991 78 2337 43.